Showing papers by "Armando Santoro published in 1987"
TL;DR: ABVD followed by extensive irradiation represents a valid therapeutic alternative to the widely used alkylating agent-containing regimens plus radiotherapy, and the comparative iatrogenic morbidity showed that irreversible gonadal dysfunction as well as acute leukemia occurred only in patients subjected to MOPP.
Abstract: In an attempt to reduce some of the delayed sequelae associated with combined modality therapy in Hodgkin's disease, we randomly tested stages IIB, IIIA, and IIIB MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) v ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine). In 232 previously untreated patients, three cycles of either combination preceded and followed extensive irradiation. The complete remission rate was 80.7% following MOPP and 92.4% following ABVD (P less than .02). The 7-year results indicated that ABVD was superior to MOPP in terms of freedom from progression (80.8% v 62.8%; P less than .002), relapse-free survival (87.7% v 77.2%; P = .06), and overall survival (77.4% v 67.9%; P = .03). Moreover, the comparative iatrogenic morbidity showed that irreversible gonadal dysfunction as well as acute leukemia occurred only in patients subjected to MOPP, while cardiopulmonary studies failed to document significant laboratory differences between the two treatment groups. Present findings indicate that ABVD followed by extensive irradiation represents a valid therapeutic alternative to the widely used alkylating agent-containing regimens plus radiotherapy.
357 citations
TL;DR: A higher response rate with less myelosuppression suggests that IFOS may have advantages over CYCLO in combination therapy, and serious infections occurred in approx.
226 citations
TL;DR: The use of equimolar doses of adriamycin and EPI in advanced soft tissue sarcoma produced response rates which did not differ significantly and were only slightly in favour of ADM, however, this was achieved at the expense of higher toxicity.
141 citations
Journal Article•
20 citations
18 citations
01 Jul 1987
TL;DR: Adriamycin and ifosfamide is a new effective combination with a 9% CR rate in good performance patients with measurable advanced soft tissue sarcoma and its proper role will now be evaluated in a randomized trial against adriamyin alone and CYVADIC.
Abstract: SummaryIn July 1984, the EORTC initiated a clinical phase-II trial with the combination of adriamycin 50 mg/m2 i. v. push and ifosfamide 5 g/m2 i. v. over 24 h with mesna rescue in previously untreated patients with measurable advanced soft tissue sarcoma. Therapy was repeated at 3 weekly intervals. Inclusion criteria were an age of 15-70 years, WHO performance status (≤ 2, WBC ≥ 3.5 s 109/1, platelets ≥ 100 × 109/1), adequate cardiac, kidney, and liver functions. As of February 1986, 204 patients were entered into the study by 26 participating institutions. Six patients were ineligible, 3 unevaluable and 33 are still too early for a preliminary response analysis. Characteristics of the 162 evaluable patients are: 85 males, 77 females, median age 48 years (range: 17–70), performance status 0:48; 1:88; 2:26 patients. The median number of treatment courses was 4 (range: 1–4). Hitherto, 14 complete remissions (CR) and 41 partial remissions (PR) have been observed, resulting in a 34% response rate (95% C. I.: 27–41%). Median time to reach PR was 7 weeks, to CR 16 weeks. Data on the duration of response are still too weak. Major toxicities encountered were leukopenia with a WBC nadir of WHO ≥ 3 in 55% of the patients already in the first course and leading to dose modifications increasing from 14% to 31% in the second to sixth course, respectively; nausea and vomiting WHO ≥ 3 in 40%; and alopecia in 92% of the patients. Other side-effects were generally mild.In conclusion, adriamycin and ifosfamide is a new effective combination with a 9% CR rate in good performance patients. Its proper role will now be evaluated in a randomized trial against adriamycin alone and CYVADIC.
3 citations